Ardelyx

Yahoo Finance • 8 days ago

Ardelyx President and CEO Sells 41,000 Shares for $243,000

Michael Raab, President & CEO of Ardelyx(NASDAQ:ARDX), reported a sale of 41,666 shares of Common Stock for a transaction value of approximately $243,000 on March 16, 2026, according to a SEC Form 4 filing. Transaction summary Metric Val... Full story

Yahoo Finance • last month

Ardelyx CEO Sells 41k Shares as Company Announces Huge Partnership

On Feb. 24, 2026, Ardelyx(NASDAQ:ARDX) President and CEO Michael Raab reported the sale of 41,666 shares of Common Stock for approximately $261,000, according to a SEC Form 4 filing. Transaction summary Metric Value Shares sold (direct)... Full story

Yahoo Finance • 2 months ago

Ardelyx to Report Full Year and Fourth Quarter 2025 Financial Results on February 19, 2026

WALTHAM, Mass., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet me... Full story

Yahoo Finance • 2 months ago

Ardelyx, Inc. (ARDX) Gains TD Analysts Support Ahead of Q4 Results

We recently compiled a list of the 20 Best Biotech Stocks Under $20 to Buy Now. Ardelyx, Inc. is next on our list. TheFly reported on January 29 that TD Cowen raised its price target on ARDX to $13 from $10 while maintaining a Buy rating.... Full story

Yahoo Finance • 5 months ago

BTIG Maintains a Buy on Ardelyx, Inc (ARDX)

​Ardelyx, Inc. (NASDAQ:ARDX) is one of the Fast-Growing Small Cap Stocks to Buy According to Analysts. On November 10, Julian Harrison from BTIG reiterated a Buy rating on Ardelyx, Inc. (NASDAQ:ARDX) with a $14 price target. However, earli... Full story

Yahoo Finance • 5 months ago

Real-World Evidence Studies of XPHOZAH® (tenapanor) Demonstrate Patient Satisfaction and Reduction in Serum Phosphate with XPHOZAH in Data Presented at ASN Kidney Week

WALTHAM, Mass., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet me... Full story

Yahoo Finance • 5 months ago

Ardelyx Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Q3 2025 product revenue of $105.5 million reflects 15% year-over-year growth IBSRELA® Q3 revenue of $78.2 million reflects 92% year-over-year growth; IBSRELA guidance raised, 2025 revenue expected to be between $270-275 million XPHOZAH®... Full story

Yahoo Finance • 5 months ago

Ardelyx Presents Data that Continues to Support the Benefits of IBSRELA® (tenapanor) at the American College of Gastroenterology’s 2025 Annual Meeting

IBSRELA patients reported treatment satisfaction in real-world survey Post-hoc analysis of T3MPO-1 and T3MPO-2 studiesdemonstrates effectiveness of IBSRELA in reducing abdominal bloating for patients with IBS-C Analysis of electronic hea... Full story

Yahoo Finance • 6 months ago

Ardelyx appoints Sue Hohenleitner as CFO

* Ardelyx (NASDAQ:ARDX [https://seekingalpha.com/symbol/ARDX]) announced on Monday the appointment [https://seekingalpha.com/pr/20263197-ardelyx-appoints-experienced-finance-executive-sue-hohenleitner-as-chief-financial-officer] of Sue H... Full story

Yahoo Finance • 6 months ago

Ardelyx to Report Third Quarter 2025 Financial Results on October 30, 2025

WALTHAM, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet me... Full story

Yahoo Finance • 6 months ago

Ardelyx Appoints Experienced Finance Executive, Sue Hohenleitner, as Chief Financial Officer

WALTHAM, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet me... Full story

Yahoo Finance • 7 months ago

Implied XBI Analyst Target Price: $142

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied... Full story

Yahoo Finance • 8 months ago

Eureka Therapeutics Appoints Dr. Reginald Seeto and William S. Solari III to Board of Directors

EMERYVILLE, Calif., August 12, 2025--(BUSINESS WIRE)--Eureka Therapeutics, Inc., a clinical-stage biotechnology company pioneering safer and more effective T-cell therapies, today announced the appointment of Dr. Reginald Seeto and William... Full story

Yahoo Finance • 8 months ago

Ardelyx raises 2025 IBSRELA revenue guidance to $250M–$260M amid sustained demand growth

Earnings Call Insights: Ardelyx (ARDX) Q2 2025 MANAGEMENT VIEW * Michael G. Raab, President and CEO, emphasized the company's strong quarter, stating "We generated $97.7 million in total revenue, representing 33% year-over-year growth,... Full story

Yahoo Finance • 8 months ago

Earnings call transcript: Ardelyx Q2 2025 beats earnings expectations

Ardelyx Inc (ARDX) reported its Q2 2025 earnings on August 4, revealing a notable earnings surprise. The company posted a net loss of $0.08 per share, beating analysts’ expectations of a $0.13 loss. Revenue reached $97.7 million, surpassin... Full story

Yahoo Finance • 8 months ago

Which stocks are moving after the closing bell on Monday?

After the closing bell on Monday, let's take a glimpse of the US markets and explore the top gainers and losers in today's after-hours session. [postmarket] TODAY'S AFTER HOURS GAINERS TICKER CHANGE COMMENT ADAP [https://www.... Full story

Yahoo Finance • 8 months ago

Ardelyx Announces Changes to the Executive Leadership Team

Edward Conner, M.D. appointed Chief Medical Officer and John Bishop, Ph.D. appointed Chief Technical Operations Officer Justin Renz, Chief Financial and Operations Officer, to transition out of the Company WALTHAM, Mass., Aug. 04, 2025... Full story

Yahoo Finance • 8 months ago

Ardelyx Reports Second Quarter 2025 Financial Results and Provides Business Update

Company reports strong commercial performance in the second quarter, recording $97.7 million in total revenue, reflecting 33% growth year-over-year IBSRELA generated net sales revenue of $65.0 million; XPHOZAH generated net sales revenue... Full story

Yahoo Finance • 8 months ago

Here are the major earnings after the close Monday

Major earnings expected after the bell on Monday include: * Palantir Technologies (PLTR [https://seekingalpha.com/symbol/PLTR]) * Simon Property Group (SPG [https://seekingalpha.com/symbol/SPG]) * MercadoLibre (MELI [https://seeking... Full story

Yahoo Finance • 8 months ago

Stocks Set to Open Higher as Investors Bet on Fed Rate Cuts

September S&P 500 E-Mini futures (ESU25 [https://www.barchart.com/futures/quotes/ESU25]) are up +0.64%, and September Nasdaq 100 E-Mini futures (NQU25 [https://www.barchart.com/futures/quotes/NQU25/overview]) are up +0.77% this morning, po... Full story